Recommending increased use of cystatin C
Cystatin C is less susceptible to factors that affect muscle mass (age, diet, sex, physical activity, etc.), as it is expressed through all nucleated cells. Individuals with similar kidney function can therefore be expected to have similar serum concentrations of cystatin C.
KDIGO recommends the clinical use of cystatin C1, and The National Kidney Foundation (NKF) in the US and the American Society of Nephrology (ASN) have also recently, in a joint taskforce, recommended to increase the use of cystatin C combined with serum (blood) creatinine2, as a confirmatory assessment of GFR or kidney function.
Webinar: Cystatin C - Now is the time...
Gentian's Global Product Manager for cystatin C, Mr Gaute Tangen is in this webinar going through the highlights of cystatin C, The NKF-ASN TaskForce recommendation of increased use of cystatin C as a confirmatory assessment of GFR as part of a race-free approach to diagnosing kidney disease, and the Gentian's cystatin C assay advantages.
Contact us for more information and validation
If you and your colleagues would like to learn more about cystatin C and how you could incorporate this test into clinical workflows within your organisation, please contact us via marketing@gentian.com or the form below:
References:
- 1–226.KDIGO Guidelines 2012 published in Kidney International Supplements Vol3 Issue 1, Jan 2013
